Solid Biosciences financials
$7.16−1.65%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$57.4M | -$57.3M | -$49.4M | -$48.1M | -$41.7M | -$40.1M | -$39.9M | -$35.2M | -$27.8M | -$26.9M | -$22.3M | -$23.1M |
| Net income | -$54.8M | -$56.7M | -$49.8M | -$45.8M | -$39.5M | -$39.3M | -$42.6M | -$32.7M | -$25.1M | -$24.3M | -$20.3M | -$21.0M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.38 | $-0.52 | $-0.52 | $-0.48 | $-0.42 | $-0.59 | $-1.00 | $-0.79 | $-0.61 | $-0.64 | $-1.00 | $-1.05 |
| EBITDA | -$57.0M | -$56.9M | -$48.9M | -$47.7M | -$41.3M | -$39.6M | -$39.4M | -$34.8M | -$26.6M | -$26.5M | -$22.1M | -$22.5M |
| Operating cash flow | -$52.6M | -$47.2M | -$53.6M | -$33.5M | -$37.4M | -$31.9M | -$29.6M | -$23.7M | -$21.5M | -$25.2M | -$20.8M | -$17.9M |
| Free cash flow | -$52.7M | -$47.4M | -$54.1M | -$33.6M | -$37.8M | -$32.0M | -$29.8M | -$23.7M | -$21.8M | -$25.3M | -$20.9M | -$18.3M |
| Diluted shares | 143.7M | 109.8M | 95.1M | 94.4M | 94.1M | 66.3M | 42.7M | 41.4M | 40.9M | 38.2M | 20.2M | 20.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $159.4M | $297.1M | $59.9M | $61.4M | $138.9M | $210.6M |
| Short-term investments | $218.3M | $83.6M | $128.0M | $174.8M | $129.2M | $96.3M |
| Total debt | $0.00 | $0.00 | $0.00 | $281.0K | $953.0K | $1.1M |
| Total assets | $420.6M | $422.9M | $232.5M | $273.9M | $308.3M | $343.9M |
| Total liabilities | $46.5M | $48.8M | $52.5M | $56.0M | $50.0M | $49.4M |
| Shareholders' equity | $374.1M | $374.1M | $180.0M | $217.9M | $258.3M | $294.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology